{"entity":{"id":"nct04614103","kind":"trial","name":"Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of LN-145 in non-small-cell lung cancer, run by Iovance Biotherapeutics, Inc., now recruiting.","summary":"Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer is a phase 2 interventional study registered as NCT04614103 by Iovance Biotherapeutics, Inc., with 170 participants planned, started 2021-05-07 and due to reach its primary completion in 2030-12. Interventions recorded: LN-145.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04614103","url":"https://clinicaltrials.gov/study/NCT04614103"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["iovance"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04614103","phase":"2","setting":"A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer","sponsor":"Iovance Biotherapeutics, Inc.","enrolled":170,"outcomes":[]},"route":"/trials/nct04614103/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"iovance","kind":"company","name":"Iovance Biotherapeutics","route":"/companies/iovance/"}]}}